AHA 2020 is still 2 months away. It will be virtual, not in person. I just checked out the program and see 4 apabetalone presentations. Go here and search for apabetalone. I haven't yet checked other potential Q4 2020 events, but I'm just bookmarking this here to remind me to double check.

Session CV19.MDP10 - Mechanisms of SARS-CoV-2 Infection: MP130 - Apabetalone (RVX-208) Reduces ACE2 Expression in Human Cell Culture Systems, Which Could Attenuate SARS-CoV-2 Viral Entry

Dean Gilham, Resverlogix Corp, Calgary, AB, Canada; Li Fu, Resverlogix Corp., Calgary, AB, Canada; Laura Miyoko Tsujikawa, Brooke Rakai, Sylwia Wasiak, Stephanie Stotz, Christopher Sarsons, Resverlogix Corp, Calgary, AB, Canada; Michael Sweeney, Jan JOHANSSON, Resverlogix Corp, San Francisco, CA; Norman Wong, Ewelina Kulikowski, Resverlogix Corp, Calgary, AB, Canada

Session AT.AOS.549 - Advances in Immune Cell Biology: 377 - BET Protein Inhibitor Apabetalone Suppresses Inflammatory Hyperactivation of Monocytes From Patients With Cardiovascular Disease and Type 2 Diabetes

Sylwia Wasiak, Resverlogix Corp, Calgary, AB, Canada; Kim Dzobo, Amsterdam UMC, Amsterdam, Netherlands; Brooke Rakai, Resverlogix Corp, Calgary, AB, Canada; Yannick Kaiser, Miranda Versloot, Mahnoush Bahjat, Amsterdam UMC, Amsterdam, Netherlands; Stephanie Stotz, Li Fu, Resverlogix Corp, Calgary, AB, Canada; Michael Sweeney, Jan JOHANSSON, Resverlogix Corp, San Francisco, CA; Norman Wong, Resverlogix Corp, Calgary, AB, Canada; Erik Stroes, Jeffrey Kroon, Amsterdam UMC, Amsterdam, Netherlands; Ewelina Kulikowski, Resverlogix Corp, Calgary, AB, Canada

Session AC.APS.07 - Impact of Treatment Interventions on Stable Coronary Artery Disease: P1437 - Cardiovascular Benefits of Apabetalone: A Meta-analysis

Hang Long Li, Qi Feng, Yue Fei, bernard cheung, The Univ of Hong Kong, Hong Kong, Hong Kong

Session LF.APS.10 - Cardiometabolic Treatment Approaches in Diverse Settings: P463 - Reduction in the Risk of Major Adverse Cardiovascular Events With Apabetalone, a Bet Protein Inhibitor, in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the Betonmace Trial

Gregory G Schwartz, Univ of Colorado Sch of Med, Aurora, CO; Stephen James Nicholls, Monash Univ, Clayton, Australia; Henry Ginsberg, Columbia Univ, New York, NY; Jan JOHANSSON, RESVERLOGIX, San Ramon, CA; Kamyar Kalantar-Zadeh, Univ of California Irvine, Orange, CA; Ewelina Kulikowski, RESVERLOGIX CORP, Calgary, AB, Canada; Peter P. Toth, CGH Medical Ctr, Rock Falls, IL; Norman Wong, RESVERLOGIX CORP, Calgary, AB, Canada; Michael Sweeney, Resverlogix Corp., Calgary, AB, Canada; Kausik K Ray, IMPERIAL COLLEGE LONDON, London, United Kingdom; On behalf of the BETonMACE investigators